Heart safety during chest radiation for cancer patients
Part of Heart & circulation clinical trials.
This study looks at how chest radiation affects heart function and the immune system, and whether it is safe in people with lung, esophageal, breast, or thymus cancer who have not had chest radiation before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a cancer diagnosis: lung cancer, metastatic lung cancer, esophageal cancer, breast cancer, or thymus tumor.
- You are scheduled to receive radiation therapy to your chest area.
- You have no known heart disease and your heart pumps blood normally (LVEF of 50% or higher).
- You are willing to sign a consent form to join the study.
- You have not had radiation to your chest in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how chest radiation treatment affects the heart and lungs in people with certain lung or esophagus cancers. It may help doctors better predict and prevent these side effects during curative (aimed at cure) radiotherapy.
This trial looks at how radiation for lung, esophageal, or breast cancer affects the heart. It may help doctors reduce heart damage in future patients.
This trial tests whether common heart medicines (statins or ACE-inhibitors) can protect the heart during cancer radiation therapy. It is for adults who are about to start chest radiation and have not taken these drugs before.
This trial is testing whether a lower radiation dose and a wearable heart monitor can reduce the risk of heart rhythm problems in people receiving chest radiation for cancer. It may help those at moderate-to-high risk of heart side effects from treatment.
This study monitors how the heart and lungs respond to radiation therapy combined with immunotherapy for locally advanced lung cancer. It aims to learn how well patients tolerate treatment and to detect early signs of side effects.
This trial tests a new way to plan radiation for cancers in the chest area (like lung, esophageal, or thymus cancers) that aims to protect the heart from high doses of radiation. It is for people who need daily radiation for at least three weeks and who are expected to live more than a year.
Hear when a new MACE, Arrhythmia, Pericardial Effusion and Survival trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.